ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Deferred Revenue (Non-current) history
Currency unavailable · from the balance sheet
No Deferred Revenue (Non-current) data reported for this period type.
Deferred Revenue (Non-current) vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $64.84M USD | +8.8% | +33.4% | 26.5% | |
| Mar 2026 | $55.22M USD | +3.6% | — | 48.0% | |
| Mar 2026 | $36.35M USD | — | — | 12.4% | |
| Mar 2026 | €17.33M EUR | -43.3% | — | 17.5% | |
| Mar 2026 | $14.6M USD | +161.4% | -53.9% | 2.5% | |
| Mar 2026 | $6.6M USD | -35.6% | -42.6% | 1.5% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -16.0% | -42.6% | 2.5% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.